ASCO 2021 Highlights

Treatment with the checkpoint inhibitor pembrolizumab (Keytruda) following surgery significantly extended disease-free survival (DFS) in patients with high-risk, clear-cell renal-cell carcinoma (RCC) compared with placebo, according to the results of the KEYNOTE-564 clinical trial. These findings were reported during a plenary session of the ASCO 2021 virtual annual meeting. Read More ›

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution. Read More ›

The addition of 177Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the ASCO 2021 virtual annual meeting. Read More ›

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or weekly e‑Newsletter.

I'd like to receive: